Regeneron Pharmaceuticals, Inc.
exchangeNASDAQ Global Select
ipo dateJan 01, 1991
full time employees11,851
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL ...Show More
Earnings per Share (Estimate)